Ashish D. Patel

Ashish D. Patel

Auto-generated profile, based on publicly available information

Ashish D. Patel

Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2024 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
APAshish D Patel
Ashish D Patel
ACAlexa Connors
Alexa Connors
MEMegan E Esch
Megan E Esch
Background: Colitis has been reported with some anti-CD20 therapies in multiple sclerosis (MS), but not previously with ofatumumab. Objectives: To report the first case of ofatumumab-associated colitis in MS and discuss its implications. Methods: Case report. Results: A 56-year-old female with relapsing-remitting multiple sclerosis (RRMS) developed severe colitis 3 months after initiating ofatumumab, requiring hospitalization and treatment discontinuation. Conclusion: This case suggests a potential class effect of anti-CD20 therapies, including ofatumumab, in relation to colitis in MS. Clinicians should monitor for gastrointestinal symptoms in MS patients receiving any anti-CD20 therapy.

29 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
GVGenaro Rodriguez Villa
Genaro Rodriguez Villa
APAshish D. Patel
Ashish D. Patel
DRDavid A. Reardon
David A. Reardon
ACAntonio Chiocca
Antonio Chiocca
Glioblastoma remains the most aggressive primary malignant brain tumor in adults, with survival largely unchanged despite advances in molecular diagnostics and supportive care. Therapeutic failure reflects fundamental biological and anatomical barriers, including intratumoral heterogeneity, an immunosuppressive tumor microenvironment, and restricted drug delivery across the blood-brain barrier. In this Review, we summarize the current standard of care and critically examine emerging strategies aimed at overcoming these constraints, including locoregional delivery technologies, immunotherapy, biomarker-defined precision approaches, and adaptive clinical trial designs. We highlight key translational and clinical studies shaping the field and discuss principles for developing more effective, integrated therapeutic paradigms.

1 December 2024 in Neurology Clinical Practice
Verified
Journal Article
Open access
APAshish D. Patel
Ashish D. Patel
MSMallory Sponenberg
Mallory Sponenberg
LWLeeann Webster
Leeann Webster
SCSara Cole
Sara Cole
ESEdward Stefanowicz
Edward Stefanowicz
SFScott Friedenberg
Scott Friedenberg
The demand for neurology services exceeds the current supply. We convened multiple stakeholders to learn what drives our primary care providers (PCPs) to refer patients with headache to our neurology practice. This information guided a collaborative effort to evaluate the impact of an electronic health record (EHR) headache tool on care delivery in our PCP clinics. Neurology referrals and MRI ordering declined by 77% and 35%, respectively, after the release of the EHR tool for an estimated savings of $207,600 over 3 months. PCPs prescribing habits minimally changed. Electronically embedding a neurologist's knowledge in our PCP office was an effective way to shape the demand for headache consultation. By further leveraging stakeholder collaboration, we plan to improve the tool and disseminate it across our health system to reduce headache burden and health care costs.